Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value

Por van Boekel, Martinus AM, Vossenaar, Erik R, van den Hoogen, Frank HJ, van Venrooij, Walther J
Publicado em 2002

Early and late outcome after single step dilatational tracheostomy versus the guide wire dilating forceps technique: a prospective randomized clinical trial

Por Fikkers, Bernard G., Staatsen, Marieke, van den Hoogen, Frank J. A., van der Hoeven, Johannes G.
Publicado em 2011

Improved insulin sensitivity by anti‐TNFα antibody treatment in patients with rheumatic diseases

Por Huvers, Frank C, Popa, Calin, Netea, Mihai G, van den Hoogen, Frank H J, Tack, Cees J
Publicado em 2007

What does the clinician need to improve patient care in systemic sclerosis?

Por Vonk, Madelon C, van den Hoogen, Frank H J, van Riel, Piet L C M, Valentini, Gabriele
Publicado em 2007

Comparison of two percutaneous tracheostomy techniques, guide wire dilating forceps and Ciaglia Blue Rhino: a sequential cohort study

Por Fikkers, Bernard G, Staatsen, Marieke, Lardenoije, Sabine GGF, van den Hoogen, Frank JA, van der Hoeven, Johannes G
Publicado em 2004

Anti-α-fodrin antibodies do not add much to the diagnosis of Sjögren's syndrome

Por Zandbelt, Michiel M, Vogelzangs, Judith, van de Putte, Leo BA, van Venrooij, Walther J, van den Hoogen, Frank HJ
Publicado em 2004

Total ankle prostheses in rheumatoid arthropathy: Outcome in 52 patients followed for 1–9 years

Por van der Heide, Huub JL, Schutte, Bernard, Louwerens, Jan Willem K, van den Hoogen, Frank H J, de Waal Malefijt, Maarten C
Publicado em 2009

Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease

Por Hof, Daniëlle, Cheung, Kalok, de Rooij, Dirk-Jan RAM, van den Hoogen, Frank H, Pruijn, Ger JM, van Venrooij, Walther J, Raats, Jos MH
Publicado em 2005

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an o...

Por van der Maas, Aatke, van den Bemt, Bart JF, Wolbink, Gertjan, van den Hoogen, Frank HJ, van Riel, Piet LCM, den Broeder, Alfons A
Publicado em 2012

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

Por van den Bemt, Bart JF, den Broeder, Alfons A, Wolbink, GJ, Hekster, Yechiel A, van Riel, Piet LCM, Benraad, Bart, van den Hoogen, Frank HJ
Publicado em 2011

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review

Por Tweehuysen, Lieke, van den Ende, Cornelia H., Beeren, Fenna M. M., Been, Evelien M. J., van den Hoogen, Frank H. J., den Broeder, Alfons A.
Publicado no Arthritis Rheumatol (2017)

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?

Por Bouman, Chantal A M, den Broeder, Alfons A, van der Maas, Aatke, van den Hoogen, Frank H J, Landewé, Robert B M, van Herwaarden, Noortje
Publicado no RMD Open (2017)

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study

Por den Broeder, Alfons A, van Herwaarden, Noortje, van der Maas, Aatke, van den Hoogen, Frank HJ, Bijlsma, Johannes W, van Vollenhoven, Ronald F, van den Bemt, Bart JF
Publicado em 2013

Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis

Por van Lieshout, Antoine W T, Fransen, Jaap, Flendrie, Marcel, Eijsbouts, Agnes M M, van den Hoogen, Frank H J, van Riel, Piet L C M, Radstake, Timothy R D J
Publicado em 2007

Cross-Language Measurement Equivalence of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis: A Comparison of Canadian and Dutch Patients

Por Kwakkenbos, Linda, Arthurs, Erin, van den Hoogen, Frank H. J., Hudson, Marie, van Lankveld, Wim G. J. M., Baron, Murray, van den Ende, Cornelia H. M., Thombs, Brett D.
Publicado em 2013

Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor α‐neutralising treatments in rheumatoid art...

Por Radstake, Timothy R D J, Fransen, Jaap, Toonen, Erik J M, Coenen, Marieke J H, Eijsbouts, Agnes E, Donn, Rachelle, van den Hoogen, Frank H J, van Riel, Piet L C M
Publicado em 2007

Validation of potential classification criteria for systemic sclerosis

Por Johnson, Sindhu R., Fransen, Jaap, Khanna, Dinesh, Baron, Murray, van den Hoogen, Frank, Medsger, Thomas A., Peschken, Christine A., Carreira, Patricia E., Riemekasten, Gabriela, Tyndall, Alan, Matucci-Cerinic, Marco, Pope, Janet E.
Publicado em 2012

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis

Por van den Bemt, Bart J F, den Broeder, Alfons A, Wolbink, Gert-Jan, van den Maas, Aatke, Hekster, Yechiel A, van Riel, Piet L C M, Benraad, H Bart, van den Hoogen, Frank H J
Publicado em 2013

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiori...

Por van Herwaarden, Noortje, van der Maas, Aatke, Minten, Michiel J M, van den Hoogen, Frank H J, Kievit, Wietske, van Vollenhoven, Ronald F, Bijlsma, Johannes W J, van den Bemt, Bart J F, den Broeder, Alfons A
Publicado no BMJ (2015)

Modulation of lipoprotein plasma concentrations during long‐term anti‐TNF therapy in patients with active rheumatoid arthritis

Por Popa, Calin, van den Hoogen, Frank H J, Radstake, Timothy R D J, Netea, Mihai G, Eijsbouts, Agnes E, den Heijer, Martin, van der Meer, Jos W M, van Riel, Piet L C M, Stalenhoef, Anton F H, Barrera, Pilar
Publicado em 2007